Acifran: Selective HM74A/GPR109A Agonist for Lipid Metabolism Research

Principle Overview: Targeting GPR109 Receptors in Lipid Signaling

The regulation of lipid metabolism is central to understanding and treating metabolic disorders such as dyslipidemia, diabetes, and atherosclerosis. Key players in this regulatory network are the hydroxycarboxylic acid receptors HM74A/GPR109A and GPR109B, both members of the G-protein coupled receptor (GPCR) family. These receptors act as metabolic sensors, modulating lipid signaling pathways in response to endogenous and exogenous agonists. Acifran, chemically known as (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid, is a highly selective agonist for HM74A/GPR109A and GPR109B, and is supplied at ≥98% purity by APExBIO.

Recent structural studies, notably the 2025 PLOS Biology article by Ye et al., have revealed the precise molecular interactions between Acifran and its target receptors. This work leveraged cryo-EM to resolve the Acifran–HCAR3 (GPR109B) complex at 3.18Å and the Acifran–HCAR2 (GPR109A) complex at 2.72Å, illuminating the structural basis for ligand selectivity and functional modulation without the adverse effects associated with some other agonists.

As a hypolipidemic agent for lipid metabolism research, Acifran enables the controlled activation of GPCRs, supporting studies on signal transduction, lipid homeostasis, and the molecular etiology of lipid-related diseases. Its robust selectivity and well-characterized binding make it the compound of choice for metabolic disorder research.

Step-by-Step Experimental Workflow with Acifran

1. Compound Preparation and Handling

• Solubility and Storage: Acifran is an off-white solid with a molecular weight of 218.21 (C₁₂H₁₀O₄). It is soluble up to 21.82 mg/mL in DMSO or ethanol. For optimal stability, store at -20°C. Prepare solutions fresh and avoid long-term storage, as activity may decrease over time.
• Weighing and Dissolution: Accurately weigh Acifran using an analytical balance. Dissolve in 100% DMSO for stock solutions (e.g., 10 mM), vortex thoroughly, and filter sterilize if required for cell-based assays.

2. Cell-Based Assay Protocols

• Cell Line Selection: Use HEK-293 or CHO cells stably expressing HM74A/GPR109A or GPR109B. For functional assays, ensure receptor expression via qPCR or immunoblotting.
• Dosing: Prepare serial dilutions of Acifran to achieve desired concentrations (e.g., 0.1–100 μM) in assay buffer. Maintain final DMSO concentration in wells at ≤0.1% to avoid cytotoxicity.
• Assay Readouts: Employ cAMP inhibition assays, as GPR109A/B are Gi-coupled. Use a luminescent or fluorescent cAMP detection kit. Incubate cells with Acifran for 30 minutes at 37°C before measuring cAMP levels.
• Controls: Include vehicle (DMSO) and positive control agonists (e.g., nicotinic acid for GPR109A) to benchmark Acifran's efficacy.

3. Structural and Mechanistic Studies

• Binding Assays: For receptor binding studies, Acifran can be used in radioligand displacement or fluorescence polarization assays to quantify affinity and selectivity.
• Cryo-EM and Docking: Leverage published 3D structures (PDB: 9JKX for Acifran–HCAR3, 9JKY for Acifran–HCAR2) to design mutagenesis or computational docking experiments, probing the molecular determinants of ligand recognition.

For a detailed, scenario-driven experimental guide, see the article "Acifran (SKU B6848): Reliable HM74A/GPR109 Agonist for Lipid Metabolism Research", which complements this protocol with troubleshooting scenarios and workflow optimization strategies.

Advanced Applications and Comparative Advantages

Precision Modulation of Lipid Signaling Pathways

Acifran’s selectivity as a G-protein coupled receptor agonist enables researchers to dissect the nuanced roles of HM74A/GPR109A and GPR109B in lipid metabolism regulation. Unlike broad-spectrum agonists, Acifran’s activity can be attributed to specific receptor-ligand interactions—validated by cryo-EM at sub-3.2Å resolution (Ye et al., 2025).

• Low Off-Target Activity: The compound’s orthosteric binding is defined by key π–π interactions with F107^3.32 in HCAR3, resulting in minimized cross-reactivity and improved interpretability of downstream signaling data.
• Quantified Performance: In functional cAMP inhibition assays, Acifran exhibits EC₅₀ values in the low micromolar range and demonstrates >95% maximal response compared to endogenous ligands, as reported in recent studies.

Structural Probe for Mechanistic Insights

Acifran is uniquely suited for use as a structural probe in drug discovery and receptor biology. Its ability to stabilize specific receptor conformations facilitates high-resolution structure determination, as described in "Acifran as a Structural Probe: Illuminating GPR109 Receptor Pharmacology". This extends the functional repertoire of Acifran from basic signaling studies to advanced applications such as:

• Structure-Guided Mutagenesis: Design and validation of receptor mutants to dissect ligand-binding determinants.
• Comparative Pharmacology: Side-by-side evaluation of Acifran and alternative agonists to map functional selectivity and pathway bias.

Workflow Reliability and Reproducibility

Compared to other HM74A/GPR109A or GPR109B agonists, Acifran’s high purity and batch-to-batch consistency, as assured by APExBIO, translate to superior reproducibility in both high-throughput screening and mechanistic studies. The article "Acifran: Selective HM74A/GPR109A Agonist for Lipid Metabolism Research" further details atomic benchmarks and dispels common misconceptions regarding its use in GPCR assay platforms.

Troubleshooting and Optimization Tips

• Solubility Issues: If Acifran does not dissolve fully, gently warm the solution (<37°C) and vortex. Avoid prolonged heating. Use freshly prepared aliquots to minimize degradation.
• Assay Variability: Standardize cell density, incubation time, and DMSO concentration. Prepare master stocks and dilute immediately before use to ensure consistency.
• Signal Saturation or Weak Response: Titrate Acifran concentrations to determine the dose-response curve. Ensure receptor expression levels are within a physiological range to avoid ceiling or floor effects.
• Batch Consistency: Source Acifran directly from APExBIO's Acifran product page to leverage their stringent quality controls and ensure traceability.
• Long-Term Storage: Avoid storing Acifran solutions; instead, keep dry powder at -20°C and prepare stocks as needed. This preserves compound activity and performance.

For additional troubleshooting scenarios and optimization strategies, see "Acifran (SKU B6848): Reliable HM74A/GPR109 Agonist for Lipid Metabolism Research", which extends this discussion with real-world lab Q&A and vendor selection advice.

Future Outlook: Expanding the Toolkit for Lipid-Related Disease Research

The structural and functional insights provided by Acifran are driving a new era in metabolic disorder research. The landmark cryo-EM study by Ye et al. paves the way for the rational design of HCAR3-selective therapeutics that avoid HCAR2-mediated adverse effects such as cutaneous flushing. Acifran’s performance as a hypolipidemic agent for lipid metabolism research positions it as a reference standard in preclinical discovery.

Ongoing research is extending Acifran’s application to in vivo models and translational biomarker studies, offering new opportunities to explore the pathophysiology of lipid-related diseases. As the toolkit for lipid signaling pathway modulation expands, Acifran will remain an essential metabolic disorder research compound, enabling the next generation of discoveries in G-protein coupled receptor biology.

In summary: For researchers seeking a proven, selective, and structurally validated GPR109A/GPR109B agonist, Acifran from APExBIO delivers robust performance and data-driven confidence for lipid metabolism regulation studies.